Matches in Wikidata for { <http://www.wikidata.org/entity/Q85885683> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q85885683 description "2013 թվականին հրատարակված գիտական հոդված" @default.
- Q85885683 description "artikull shkencor i botuar më 01 janar 2013" @default.
- Q85885683 description "artículu científicu espublizáu en xineru de 2013" @default.
- Q85885683 description "im Jahr 2013 veröffentlichter wissenschaftlicher Artikel" @default.
- Q85885683 description "scientific article published on 01 January 2013" @default.
- Q85885683 description "wetenschappelijk artikel" @default.
- Q85885683 description "наукова стаття, опублікована в січні 2013" @default.
- Q85885683 description "научна статия" @default.
- Q85885683 name "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 name "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 name "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 type Item @default.
- Q85885683 label "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 label "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 label "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 prefLabel "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 prefLabel "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 prefLabel "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 P1433 Q85885683-082C2C42-2674-4CF0-973A-2E96CA911DB7 @default.
- Q85885683 P1476 Q85885683-CD438CBC-8314-4245-AE43-6A02743103C0 @default.
- Q85885683 P2093 Q85885683-D1AD5411-2256-4749-AFFD-154D43933467 @default.
- Q85885683 P304 Q85885683-7DDEBD72-CCCA-449A-853E-5E7C52E7F921 @default.
- Q85885683 P31 Q85885683-C1C2517F-4D23-42A7-9331-C29B81EEC9CE @default.
- Q85885683 P356 Q85885683-0A8AB768-92D8-4DC9-B439-348C7C5ECEBB @default.
- Q85885683 P433 Q85885683-5E4ED755-105C-457B-AA82-ABEF361E050F @default.
- Q85885683 P478 Q85885683-7B0F3E1D-6B4C-48D5-B38E-B19DAAFE4384 @default.
- Q85885683 P577 Q85885683-23F7D09D-1C03-40B7-BEAF-1CC1F15BA640 @default.
- Q85885683 P698 Q85885683-E5BA2B3E-1C02-4ED1-B1EE-7FA8A42ADDF4 @default.
- Q85885683 P356 1352458512470312 @default.
- Q85885683 P698 23303881 @default.
- Q85885683 P1433 Q1952449 @default.
- Q85885683 P1476 "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no" @default.
- Q85885683 P2093 "Jan Hillert" @default.
- Q85885683 P304 "26-28" @default.
- Q85885683 P31 Q13442814 @default.
- Q85885683 P356 "10.1177/1352458512470312" @default.
- Q85885683 P433 "1" @default.
- Q85885683 P478 "19" @default.
- Q85885683 P577 "2013-01-01T00:00:00Z" @default.
- Q85885683 P698 "23303881" @default.